You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,039,808

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,039,808

Title:	Method of treating or improving neurological function in a human subject
Abstract:	A method of treating or improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autism spectrum condition, cerebral palsy; or ischemic long term treatment for remote ischemic or traumatic brain injury; and administering to the human subject a composition comprising a pharmaceutically effective dose of filgrastim.
Inventor(s):	Chez; Michael (Granite City, CA)
Assignee:
Application Number:	14/886,231
Patent Claims:	1. A method of treatment, comprising: identifying a human subject diagnosed with an autism spectrum disorder; and administering to the human subject a composition comprising a therapeutically effective dose of filgrastim, wherein said composition comprises no stem cells and no bone marrow suppression agent. 2. A method according to claim 1, wherein the administering is via injection of the composition. 3. A method according to claim 1, wherein the pharmaceutically effective dose comprises about 100-10,000 micrograms of filgrastim. 4. A method according to claim 1, wherein said method comprises no harvesting, reimplantation, or reinfusion of stem cells. 5. A method according to claim 1, wherein no pretreatment for immunosuppression is provided. 6. A method according to claim 1, wherein said composition comprises no blood. 7. A method according to claim 1, further comprising measuring the human subject's motor function, speech function, or social skills after said administering. 8. A method according to claim 1, wherein the autism spectrum disorder comprises pervasive development disorder, autism, or Asperger's. 9. A method for treatment, comprising: identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, or traumatic brain injury; and administering to the human subject a composition comprising a therapeutically effective dose of filgrastim, wherein said composition comprises no stem cells and no bone marrow suppression agent, wherein a first administering of the composition is at least 6 months after an initial trauma, brain injury, or concussion. 10. A method according to claim 9, wherein a first administering of the composition occurs at least 1 year after an initial trauma, brain injury or concussion. 11. A method according to claim 9, wherein a first administering of the composition is at least 2 years after an initial trauma, brain injury, or concussion. 12. A method according to claim 9, wherein the human subject has remote persisting symptoms of traumatic brain injury at least one year after an initial trauma or concussion, and the human subject is chronically stabilized in a post-injury state.

Details for Patent 10,039,808

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991	⤷ Try a Trial	2039-02-26
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.